While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...

Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

Many adults with obstructive hypertrophic cardiomyopathy (oHCM) taking mavacamten experienced new atrial fibrillation or flutter, new-onset heart failure, and frequent acute care use within months of ...

Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...

Advances in CAR T-cell therapy and bispecific antibodies have expanded treatment options, though access challenges remain. Medicaid expansion has enhanced cancer care in Louisiana, boosting access to ...

Advanced tumor stage and the presence of a stoma were identified as the strongest predictors of reduced quality of life (QOL) in patients with colorectal cancer (CRC), according to new research. 1 ...

The Affordable Care Act (ACA) subsidies and some of the CMS Innovation Center models are set to expire on December 31, 2025, with little prospect for equivalent and affordable alternatives for ...

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and ...

While artificial intelligence showed empathy and precision in respiratory health care, its equitable adoption is paramount to prevent the widening digital divide, as highlighted at the European ...

Secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves overall survival in ...

Today, the FDA approved durvalumab (Imfinzi; AstraZeneca) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as a neoadjuvant and adjuvant treatment, followed ...